Today, there are many evidence-based intervention and medication options for the treatment of substance use disorders. We at CLARE|MATRIX are proud to have been a part of research studies that have evaluated the effectiveness of medications and cognitive/behavioral treatments.

Our clinical locations have functioned as clinical sites in collaboration with researchers from UCLA, National Institute of Drug Abuse (NIDA), Substance Abuse and Mental Health Services Administration (SAMHSA), and the private industry.

Research Participation

CLARE|MATRIX has established a reputation for consistently meeting recruitment goals and conducting protocols at a high level of integrity. As a result, we have been contracted to participate in more than a dozen clinical research trials. Over the past 30 years, we have participated in many multi-site trials aimed at investigating new behavioral and pharmacological treatments for substance use disorders.

CLARE|MATRIX is available to participate as a clinical site for future clinical trials involving medication and/or psychosocial treatment for substance use disorders. We are also interested in research involving the Matrix Model for Adults, Adolescents, and Criminal Justice, and may provide Matrix Model materials to researchers wishing to investigate psychosocial addiction treatments.

Read more about the key characteristics of CLARE|MATRIX’s research practices.

If you would like more information about research at CLARE | MATRIX or are interested in participating in one of our current clinical trials, please input your name, phone and email below, which will be kept confidential. A CLARE|MATRIX team member will contact you soon.

Our Research History

  • 1990: Desipramine for stimulants (NIDA)
  • 1992: Enhanced methadone/LAAM treatment (NIDA)
  • 1993: Ritanserin for cocaine (Janssen Pharmaceuticals)
  • 1993: Naltrexone for alcohol (Dupont Pharmaceuticals)
  • 1994: Naltrexone plus Matrix for opiates (NIDA)
  • 1995: CBT & CM for cocaine (NIDA)
  • 1995: CBT & CM for stimulant-users on methadone (NIDA)
  • 1996: Acamprosate for alcohol (Lipha Pharm.)
  • 1997: Evaluation of SP 39166 for cocaine (Shering-Plough Pharmaceuticals)
  • 1998: Methamphetamine Treatment Project: Matrix Model vs. Treatment as Usual for Methamphetamine Dependence (CSAT) CM ** We achieved Evidence-based Treatment status as a result
  • 2000: Naltrel for alcohol (Drug Abuse Sciences)
  • 2000: Office-based buprenorphine (NIDA)
  • 2000: ADL-8-2698 for opioid-induced GI dysfunction (Adolor Corporation)
  • 2001: Viracept efficacy, safety, and PK with methadone (Agouron Pharmaceuticals) LA2002 Matrix & incentives vs Matrix only with methamphetamine users (NIDA-CTN)
  • 2003: Double-blind, Placebo-Controlled Evaluation of Ondansetron for methamphetamine dependence (NIDA)
  • 2003: Double-blind, Placebo-Controlled Evaluation of Bupropion for methamphetamine dependence (NIDA)
  • 2004: Effective Adolescent Treatment (CSAT) MET/CBT-5 (our WLA BAT Program)
  • 2004: Safer Sex Skills for Men in Outpatient Drug Treatment (NIDA-CTN)
  • 2005: Gabapentin and pain tolerance in methadone patients (NIDA)
  • 2006: Double-blind, Placebo-Controlled Evaluation of Topiramate for methamphetamine dependence (NIDA)
  • 2007: Double-blind, Placebo-Controlled Evaluation of Modafinil for Methamphetamine (NIDA-VA)
  • 2007: Starting treatment with agonist replacement therapies (methadone and buprenorphine, NIDA)
  • 2007-10: Four models of telephone support in aftercare (NIDA)
  • 2011: Double-blind, Placebo-Controlled Evaluation of vigabatrin for cocaine (NIDA-VA) LA2013-2015 Double-blind, Placebo-Controlled Evaluation of nepicastat for cocaine (NIDA)
  • 2013-15: Double-blind, Placebo-Controlled Evaluation of nepicastat for cocaine (NIDA)
  • 2018-Present: Treatment for Comorbid Social Anxiety and Alcohol Use Disorders (UCLA)
  • 2018-Present: Exercise in Methamphetamine Use Disorder Upregulation and Neural Function (UCLA)